JCAD can interact with large tumor suppressor kinase 2 (LATS2), thereby inhibiting the ability of LATS2 to phosphorylate yes-associated protein (YAP) in hepatoma cells in vitro [30]. This evidence concerns the gene LATS2 and hepatocellular carcinoma.